Fig. 2

NK cell ligand expression by intracranial GSC xenografts in the presence or absence of temozolomide therapy. (A) MICA immunohistochemical staining of proneural (GSC528) and mesenchymal (GSC1123 and GSC83) intracranial xenografts in SCID mice (magnification = 200X (size bar = 50 μm). (B-C) FACS analysis of NK ligand expression in dissociated GSC1123 intracranial tumours. MICA (B) and ULBP-2/5/6 (C) expression by cancer cells in mice either untreated (Control) or 48 h post temozolomide (TMZ) treatment. Mean fluorescence intensity +/- SEM (right side panels in B and C) and corresponding FACS histograms; Unstained GSC123 cells (blue), MICA- or ULBP-2/5/6-stained GSC1123 control cells from culture (red), and three independent stained GSC1123 cell populations (n = 3) isolated from untreated (light green, dark green and pink) or TMZ treated tumours (light purple, dark purple and dark blue). Statistical analysis by unpaired T-test, ** p < 0.01